Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Ahlawat S, Blakeley JO, Langmead S, Belzberg AJ, Fayad LM.

Skeletal Radiol. 2019 Aug 8. doi: 10.1007/s00256-019-03290-1. [Epub ahead of print] Review.

PMID:
31396668
2.

Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM.

Neurology. 2019 Sep 10;93(11):e1076-e1084. doi: 10.1212/WNL.0000000000008092. Epub 2019 Aug 8.

PMID:
31395668
3.

Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy.

Jiang S, Eberhart CG, Lim M, Heo HY, Zhang Y, Blair L, Wen Z, Holdhoff M, Lin D, Huang P, Qin H, Quinones-Hinojosa A, Weingart JD, Barker PB, Pomper MG, Laterra J, van Zijl PCM, Blakeley JO, Zhou J.

Clin Cancer Res. 2019 Jan 15;25(2):552-561. doi: 10.1158/1078-0432.CCR-18-1233. Epub 2018 Oct 26.

PMID:
30366937
4.

Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.

Blakeley JO, Grossman SA, Chi AS, Mikkelsen T, Rosenfeld MR, Ahluwalia MS, Nabors LB, Eichler A, Ribas IG, Desideri S, Ye X; Adult Brain Tumor Consortium.

Clin Cancer Res. 2019 Jan 1;25(1):73-79. doi: 10.1158/1078-0432.CCR-18-0110. Epub 2018 Aug 21.

PMID:
30131387
5.

Germline and Somatic NF1 Alterations Are Linked to Increased HER2 Expression in Breast Cancer.

Wang X, Kallionpää RA, Gonzales PR, Chitale DA, Tousignant RN, Crowley JP, Chen Z, Yoder SJ, Blakeley JO, Acosta MT, Korf BR, Messiaen LM, Tainsky MA.

Cancer Prev Res (Phila). 2018 Oct;11(10):655-664. doi: 10.1158/1940-6207.CAPR-18-0072. Epub 2018 Aug 13.

PMID:
30104415
6.

Clinical trial design for cutaneous neurofibromas.

Cannon A, Jarnagin K, Korf B, Widemann BC, Casey D, Ko HS, Blakeley JO, Verma SK, Pichard DC.

Neurology. 2018 Jul 10;91(2 Suppl 1):S31-S37. doi: 10.1212/WNL.0000000000005790.

PMID:
29987133
7.

Considerations for development of therapies for cutaneous neurofibroma.

Verma SK, Riccardi VM, Plotkin SR, Weinberg H, Anderson RR, Blakeley JO, Jarnagin K, Lee J.

Neurology. 2018 Jul 10;91(2 Suppl 1):S21-S30. doi: 10.1212/WNL.0000000000005791.

PMID:
29987132
8.

The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities.

Brosseau JP, Pichard DC, Legius EH, Wolkenstein P, Lavker RM, Blakeley JO, Riccardi VM, Verma SK, Brownell I, Le LQ.

Neurology. 2018 Jul 10;91(2 Suppl 1):S14-S20. doi: 10.1212/WNL.0000000000005788.

PMID:
29987131
9.

Cutaneous neurofibromas: Current clinical and pathologic issues.

Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A.

Neurology. 2018 Jul 10;91(2 Suppl 1):S5-S13. doi: 10.1212/WNL.0000000000005792.

PMID:
29987130
10.

Creating a comprehensive research strategy for cutaneous neurofibromas.

Blakeley JO, Wolkenstein P, Widemann BC, Lee J, Le LQ, Jackson R, Stathis M, Verma SK.

Neurology. 2018 Jul 10;91(2 Suppl 1):S1-S4. doi: 10.1212/WNL.0000000000005789.

PMID:
29987129
11.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

12.

Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.

Ferrer M, Gosline SJC, Stathis M, Zhang X, Guo X, Guha R, Ryman DA, Wallace MR, Kasch-Semenza L, Hao H, Ingersoll R, Mohr D, Thomas C, Verma S, Guinney J, Blakeley JO.

Sci Data. 2018 Jun 12;5:180106. doi: 10.1038/sdata.2018.106.

13.

Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.

Huang V, Bergner AL, Halpin C, Merker VL, Sheridan MR, Widemann BC, Blakeley JO, Plotkin SR.

Otol Neurotol. 2018 Jun;39(5):632-638. doi: 10.1097/MAO.0000000000001781.

14.

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.

Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, Leeper H, Mendoza T, Nayak L, Reijneveld JC, Le Rhun E, Walbert T, Weller M, Wen PY, Taphoorn MJB.

Lancet Oncol. 2018 Mar;19(3):e173-e180. doi: 10.1016/S1470-2045(18)30004-4. Review.

PMID:
29508764
15.

Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848.

Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, Hsiao MC, Chen Z, Balasubramanian M, Barnett CP, Becker TA, Ben-Shachar S, Bertola DR, Blakeley JO, Burkitt-Wright EMM, Callaway A, Crenshaw M, Cunha KS, Cunningham M, D'Agostino MD, Dahan K, De Luca A, Destrée A, Dhamija R, Eoli M, Evans DGR, Galvin-Parton P, George-Abraham JK, Gripp KW, Guevara-Campos J, Hanchard NA, Hernández-Chico C, Immken L, Janssens S, Jones KJ, Keena BA, Kochhar A, Liebelt J, Martir-Negron A, Mahoney MJ, Maystadt I, McDougall C, McEntagart M, Mendelsohn N, Miller DT, Mortier G, Morton J, Pappas J, Plotkin SR, Pond D, Rosenbaum K, Rubin K, Russell L, Rutledge LS, Saletti V, Schonberg R, Schreiber A, Seidel M, Siqveland E, Stockton DW, Trevisson E, Ullrich NJ, Upadhyaya M, van Minkelen R, Verhelst H, Wallace MR, Yap YS, Zackai E, Zonana J, Zurcher V, Claes K, Martin Y, Korf BR, Legius E, Messiaen LM.

Am J Hum Genet. 2018 Jan 4;102(1):69-87. doi: 10.1016/j.ajhg.2017.12.001. Epub 2017 Dec 28.

16.

Effect of ketogenic diets on leukocyte counts in patients with epilepsy.

Schreck KC, Lwin M, Strowd RE, Henry-Barron BJ, Blakeley JO, Cervenka MC.

Nutr Neurosci. 2019 Jul;22(7):522-527. doi: 10.1080/1028415X.2017.1416740. Epub 2017 Dec 18.

PMID:
29254457
17.

Common Histologically Benign Tumors of the Brain.

Strowd RE 3rd, Blakeley JO.

Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1680-1708. doi: 10.1212/CON.0000000000000541. Review.

PMID:
29200117
18.

Voice and Swallowing Dysfunction in Neurofibromatosis 2.

Best SR, Ahn J, Langmead S, Dhillon V, Hillel AT, Akst LM, Blakeley JO.

Otolaryngol Head Neck Surg. 2018 Mar;158(3):505-510. doi: 10.1177/0194599817741839. Epub 2017 Nov 21.

PMID:
29160153
19.

Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer.

Wang X, Teer JK, Tousignant RN, Levin AM, Boulware D, Chitale DA, Shaw BM, Chen Z, Zhang Y, Blakeley JO, Acosta MT, Messiaen LM, Korf BR, Tainsky MA.

Genes Chromosomes Cancer. 2018 Jan;57(1):19-27. doi: 10.1002/gcc.22503. Epub 2017 Sep 30.

PMID:
28891274
20.

The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.

Paldor I, Abbadi S, Bonne N, Ye X, Rodriguez FJ, Rowshanshad D, Itzoe M, Vigilar V, Giovannini M, Brem H, Blakeley JO, Tyler BM.

J Neurooncol. 2017 Oct;135(1):47-56. doi: 10.1007/s11060-017-2567-9. Epub 2017 Jul 22.

PMID:
28735458
21.

Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas.

Jiang S, Eberhart CG, Zhang Y, Heo HY, Wen Z, Blair L, Qin H, Lim M, Quinones-Hinojosa A, Weingart JD, Barker PB, Pomper MG, Laterra J, van Zijl PCM, Blakeley JO, Zhou J.

Eur J Cancer. 2017 Sep;83:9-18. doi: 10.1016/j.ejca.2017.06.009. Epub 2017 Jul 10.

22.

The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.

Blakeley JO, Bakker A, Barker A, Clapp W, Ferner R, Fisher MJ, Giovannini M, Gutmann DH, Karajannis MA, Kissil JL, Legius E, Lloyd AC, Packer RJ, Ramesh V, Riccardi VM, Stevenson DA, Ullrich NJ, Upadhyaya M, Stemmer-Rachamimov A.

Am J Med Genet A. 2017 Jun;173(6):1714-1721. doi: 10.1002/ajmg.a.38239. Epub 2017 Apr 24.

23.

Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.

Staedtke V, Bai RY, Blakeley JO.

Neurotherapeutics. 2017 Apr;14(2):298-306. doi: 10.1007/s13311-017-0518-y. Review.

24.

Current status and recommendations for biomarkers and biobanking in neurofibromatosis.

Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR; REiNS International Collaboration.

Neurology. 2016 Aug 16;87(7 Suppl 1):S40-8. doi: 10.1212/WNL.0000000000002932.

25.

Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.

Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO; Whole Body MRI Committee for the REiNS International Collaboration; REiNS International Collaboration Members 2016.

Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929.

26.

Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.

Plotkin SR, Davis SD, Robertson KA, Akshintala S, Allen J, Fisher MJ, Blakeley JO, Widemann BC, Ferner RE, Marcus CL; REiNS International Collaboration.

Neurology. 2016 Aug 16;87(7 Suppl 1):S13-20. doi: 10.1212/WNL.0000000000002933.

27.

Cutaneous manifestations in neuro-oncology: clinically relevant tumor and treatment associated dermatologic findings.

Strowd RE, Strowd LC, Blakeley JO.

Semin Oncol. 2016 Jun;43(3):401-7. doi: 10.1053/j.seminoncol.2016.02.029. Epub 2016 Feb 23. Review.

PMID:
27178695
28.

Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1.

Strowd RE 3rd, Rodriguez FJ, McLendon RE, Vredenburgh JJ, Chance AB, Jallo G, Olivi A, Ahn ES, Blakeley JO.

Am J Med Genet A. 2016 Jun;170(6):1455-61. doi: 10.1002/ajmg.a.37622. Epub 2016 Mar 14.

29.

Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis.

Ahlawat S, Baig A, Blakeley JO, Jacobs MA, Fayad LM.

J Magn Reson Imaging. 2016 Oct;44(4):794-803. doi: 10.1002/jmri.25236. Epub 2016 Mar 17.

PMID:
26991037
30.

Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS.

Neuro Oncol. 2016 Mar;18 Suppl 2:ii13-ii20. doi: 10.1093/neuonc/nov291. Review.

31.

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR.

J Clin Oncol. 2016 May 10;34(14):1669-75. doi: 10.1200/JCO.2015.64.3817. Epub 2016 Mar 14.

32.

Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Blakeley JO, Plotkin SR.

Neuro Oncol. 2016 May;18(5):624-38. doi: 10.1093/neuonc/nov200. Epub 2016 Feb 6. Review.

33.

Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas.

Ma B, Blakeley JO, Hong X, Zhang H, Jiang S, Blair L, Zhang Y, Heo HY, Zhang M, van Zijl PC, Zhou J.

J Magn Reson Imaging. 2016 Aug;44(2):456-62. doi: 10.1002/jmri.25159. Epub 2016 Jan 20.

34.

Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors.

Strowd RE, Cervenka MC, Henry BJ, Kossoff EH, Hartman AL, Blakeley JO.

Neurooncol Pract. 2015 Sep;2(3):127-136. Epub 2015 May 26.

35.

Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.

Blakeley JO, Grossman SA, Mikkelsen T, Rosenfeld MR, Peereboom D, Nabors LB, Chi AS, Emmons G, Garcia Ribas I, Supko JG, Desideri S, Ye X.

J Neurooncol. 2015 Oct;125(1):123-31. doi: 10.1007/s11060-015-1876-0. Epub 2015 Aug 19.

36.
37.

Update from the 2013 International Neurofibromatosis Conference.

Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC.

Am J Med Genet A. 2014 Dec;164A(12):2969-78. doi: 10.1002/ajmg.a.36754. Epub 2014 Sep 24. No abstract available.

38.

Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.

Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, Madanecki P, Fu C, Crowley MR, Crossman DK, Armstrong L, Babovic-Vuksanovic D, Bergner A, Blakeley JO, Blumenthal AL, Daniels MS, Feit H, Gardner K, Hurst S, Kobelka C, Lee C, Nagy R, Rauen KA, Slopis JM, Suwannarat P, Westman JA, Zanko A, Korf BR, Messiaen LM.

Nat Genet. 2014 Feb;46(2):182-7. doi: 10.1038/ng.2855. Epub 2013 Dec 22.

39.

Characterization of peripheral nerve sheath tumors with 3T proton MR spectroscopy.

Fayad LM, Wang X, Blakeley JO, Durand DJ, Jacobs MA, Demehri S, Subhawong TK, Soldatos T, Barker PB.

AJNR Am J Neuroradiol. 2014 May;35(5):1035-41. doi: 10.3174/ajnr.A3778. Epub 2013 Nov 28.

40.

Conclusions and future directions for the REiNS International Collaboration.

Widemann BC, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Plotkin SR.

Neurology. 2013 Nov 19;81(21 Suppl 1):S41-4. doi: 10.1212/01.wnl.0000435748.79908.c5.

41.

Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.

Plotkin SR, Ardern-Holmes SL, Barker FG 2nd, Blakeley JO, Evans DG, Ferner RE, Hadlock TA, Halpin C; REiNS International Collaboration.

Neurology. 2013 Nov 19;81(21 Suppl 1):S25-32. doi: 10.1212/01.wnl.0000435746.02780.f6.

42.

Achieving consensus for clinical trials: the REiNS International Collaboration.

Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC.

Neurology. 2013 Nov 19;81(21 Suppl 1):S1-5. doi: 10.1212/01.wnl.0000435743.49414.b6. Review.

43.

Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.

Grossman R, Brastianos H, Blakeley JO, Mangraviti A, Lal B, Zadnik P, Hwang L, Wicks RT, Goodwin RC, Brem H, Tyler B.

J Neurooncol. 2014 Jan;116(1):59-65. doi: 10.1007/s11060-013-1268-2. Epub 2013 Nov 2.

44.

Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma.

He J, Wu J, Jiao Y, Rodriguez FJ, Blakeley JO, Kinzler KW, Papadopoulos N, Vogelstein B, Holdhoff M.

J Neurooncol. 2013 Sep;114(3):275-9. doi: 10.1007/s11060-013-1182-7. Epub 2013 Jul 5.

45.

Histopathological correlates with survival in reoperated glioblastomas.

Woodworth GF, Garzon-Muvdi T, Ye X, Blakeley JO, Weingart JD, Burger PC.

J Neurooncol. 2013 Jul;113(3):485-93. doi: 10.1007/s11060-013-1141-3. Epub 2013 May 11.

46.

Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.

Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H.

Cancer Chemother Pharmacol. 2013 Jul;72(1):93-100. doi: 10.1007/s00280-013-2172-3. Epub 2013 May 7.

47.

Plexiform nerve sheath tumor or vascular malformation--role of advanced MR neurography and diffusion tensor imaging.

Jalali-Farahani S, Blakeley JO, Belzberg AJ, Carrino JA, Chhabra A.

Skeletal Radiol. 2013 Jul;42(7):1007-10. doi: 10.1007/s00256-013-1594-7. Epub 2013 Mar 22.

48.

Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement.

Zhou J, Zhu H, Lim M, Blair L, Quinones-Hinojosa A, Messina SA, Eberhart CG, Pomper MG, Laterra J, Barker PB, van Zijl PC, Blakeley JO.

J Magn Reson Imaging. 2013 Nov;38(5):1119-28. doi: 10.1002/jmri.24067. Epub 2013 Feb 25.

49.

Optimizing biologically targeted clinical trials for neurofibromatosis.

Gutmann DH, Blakeley JO, Korf BR, Packer RJ.

Expert Opin Investig Drugs. 2013 Apr;22(4):443-62. doi: 10.1517/13543784.2013.772979. Epub 2013 Feb 21. Review.

50.

Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M.

Am J Med Genet A. 2013 Mar;161A(3):405-16. doi: 10.1002/ajmg.a.35760. Epub 2013 Feb 7.

Supplemental Content

Loading ...
Support Center